Rationale
The current pipeline of new TB drugs has more potential now than it ever had over the last fifty years. Several international consortia are undertaking a new wave of clinical trials investigating various drug combinations including new compounds for TB treatment. The increased number and complexity of TB clinical trials requires better mechanisms for optimal sharing of knowledge, best practices, and advancements in trial designs to enable and maximize scientific knowledge, gains and benefits for clinical trial participants and investigators.
Goals and Objective
The overall goal of KITT is to accelerate TB drug and regimen development through synergizing global efforts and reducing duplication and competition for scarce resources. KITT aims to create an inclusive, collaborative framework for relevant consortia and groups involved in TB treatment R&D to share trial plans, designs, information and data to advance research outcomes.
Expected Outcome
KITT members will establish a global community of TB drug trialists to enable sharing of ideas and plans, and to build trust for the sharing of more sensitive information, when appropriate, during ad-hoc tracks collaboration. Through early sharing of knowledge, KITT will stimulate the creation of model-informed drug development frameworks for the generation of new knowledge-based TB treatments.
Highlights
No posts
|
Name |
Organization |
|
Christian Lienhardt |
CRDF Global |
|
Debra Flood |
Gates Foundation |
|
Derek Sloan |
University of St Andrews and Radboudumc |
|
Gerry Davies |
University of Liverpoll |
|
Guy Thwaites |
OUCRU |
|
Julia Lischke |
Lygature |
|
Norbert Heinrich |
LMU |
|
Patrick Phillips |
UCSF |
|
Simon Tiberi |
GSK |
|
WG Number |
WG Title |
WG co-leads |
|
WGWG1 |
Development of a clinically meaningful and harmonized grading of AEs |
Sharon Nachman Wendy Carr |
|
WG3 |
Development of harmonized outcome endpoints for efficacy and safety that are agreeable to the larger research community. |
Patrick Philips Gerry Davies |
|
WG4 |
Person-Centred Outcome Measures and Community Engagement in TB trials |
Hanif Esmail Simon Tiberi |
|
WG5 |
Data sharing and management – including individual-level patient and summary-level trial data, protocols, reasons for trials failing screening, etc. |
Rick Liwski Simon Tiberi |
|
WG6 |
Novel Trial Designs |
Patrick Philips Gerry Davies |
|
WG7 |
Deepening analysis of quantitative mycobacteriological data |
Elin Svensson Andreas Diacon |
|
WG9 |
Pragmatic TB Treatment Trials |
Patrick Philips Samuel Schumacher |